论文部分内容阅读
最新研究显示,CellTherapeutics公司研制的紫杉醇水溶性聚合物结合型制剂PGTXL用于放疗可起重要作用,极大地拓展了紫杉醇的适应证。临床前研究表明,这种新型制剂可显著提高肿瘤细胞对放疗的细胞毒性作用的敏感性,而具美国放射学院估计,有1/2
The latest research shows that CellTherapeutics company developed paclitaxel water-soluble polymer combination type PG TXL for radiotherapy can play an important role, greatly expanded the indication of paclitaxel. Preclinical studies have shown that this novel formulation can significantly increase the sensitivity of tumor cells to the cytotoxic effects of radiation, with the United States Radiation Academy estimates that 1/2